Just a few days after Pfizer’s announcement of its vaccine contender being 90% effective, US Pharmaceutical giant Moderna has also come out with its records, standing strong at showing a 94.5% response towards effectively combatting and preventing the coronavirus.
Moderna Inc, on Monday, announced that the independent NIH-appointed Data Safety Monitoring Board (DSMB) for the Phase 3 study of its mRNA-1273 vaccine candidate against COVID-19, has shown that the company’s experimental vaccine is 94.5% effective in preventing novel coronavirus.
“This is a pivotal moment in the development of our COVID-19 vaccine candidate. Since early January, we have chased this virus with the intent to protect as many people around the world as possible. All along, we have known that each day matters,” said Stephane Bancel, CEO of Moderna. “This positive interim analysis from our Phase 3 study has given us the first clinical validation that our vaccine can prevent COVID-19 disease, including severe disease,” Bancel added.
The study, known as the COVE study held by Moderna in testing the vaccine, enrolled more than 30,000 participants in the US and is being conducted in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), and the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services.
Moderna’s first analysis was based on 95 cases of COVID-19, 90 of which received a placebo with 5 receiving the vaccine. There were 11 severe cases in the placebo group and none among those that got the vaccine. The 95 cases included 15 adults aged 65 or over, and 20 participants from diverse communities including 12 people who identified as Hispanic, 4 Black Americans, 3 Asian Americans, and 1 person who was multiracial.
Going further, Moderna now plans to submit applications for authorizations to global regulatory agencies and is looking forward to the next major milestone of submitting for an emergency use authorization in the US. Bancel claimed, “while we continue to collect data on the safety and efficacy of the vaccine in the COVE study, we remain committed to and focused on doing our part to help end the COVID-19 pandemic. By the end of 2020, the company expects to have approximately 20 million doses of mRNA-1273 ready to ship in the US. The Company remains on track to manufacture 500 million to 1 billion doses globally in 2021.
Moderna, under the leadership of President Trump, has received nearly $1 billion in research and development funding from the US government and has a deal worth $1.5 billion to supply 100 million doses.